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Abstract 
 
Between spring 1982 and autumn 1984 the physiological role of inositol 1,4,5-
trisphosphate as a calcium-mobilising second messenger was first suggested and then 
experimentally established. At the same time the unexpected complexity of inositide 
metabolism began to be exposed by the discovery of inositol 1,3,4-trisphosphate. This 
article recalls my entanglement with these two inositol phosphates. 
 
Introduction (2015) 
 This is a personal recollection of events surrounding some scientific discoveries 
that took place in what were for me two and a half remarkable years, from spring 1982 to 
autumn 1984. During this time the second messenger function of inositol 1,4,5-
trisphosphate (Ins(1,4,5)P3) was established, from first suggestions right through to more-
or-less universal acceptance. The period also included the discovery and elucidation of 
the isomeric configuration of inositol 1,3,4-trisphosphate (Ins(1,3,4)P3), which, as the 
account below shows, also occupied much of my attention. From a 21st Century 
perspective (e.g. [1]), it can be seen that the real significance of Ins(1,3,4)P3 is as the 
starting point of the unexpected and awesome proliferation of inositol phosphates and 
lipids and their functions that ensued in the 80's and 90's [2, 3]. But at the time its 
discovery, although implying that things were more complicated than we thought, was 
really just another facet of the story of Ins(1,4,5)P3, with which it was inextricably 
entwined. 
 This account was originally hand-written in a single session during an 
unscheduled eight hour wait in an airport (Detroit, I think) in 1987. I had exhausted my 
stamina for reading and while drinking a beer or two fell to musing over what had 
happened over the previous hectic few years; to alleviate the interminable waiting I wrote 
it all down.  I came across the pile of hand-written pages during an office clear-out when 
I changed jobs in 1996 and I used an excerpt of it as the basis for a short article about the 
discovery of Ins(1,3,4,5)P4 [4]. Here I have simply transcribed the rest of it. Although 
while doing that I have smoothed over the worst colloquialisms, removed profanities and 
inserted some references and a few perspectives [any 21st Century thoughts are 
distinguished by being placed in square brackets], I have resisted the temptation to tidy it 
up into a flawless piece of prose because it is very much a personal narrative. Charles 
Fernyhough has argued in his book ‘Pieces of Light’ [5] that remembering is a flawed 
process even when the writing down happens shortly after the events remembered, so I 
should emphasise that this account is how I saw it all in 1987 and I apologise to any of 
the people mentioned below if they remember anything differently. 
 
 
1982 
 The story really began for me with a meeting held at the AFRC Insitute of Animal 
Physiology [now the Babraham Institute] in Rex Dawson's office some time in March 
1982; I've lost the diary of that year so the exact date is unknown. I had been trying for 
some months to label platelets with [3H]-inositol so that I could stimulate them with 
thrombin and see which inositol phosphate appeared first. This experiment was inspired 
by, and was designed to test, the proposition (which was in turn a resurrection of an 
earlier idea [6]) that we had heard the previous autumn from Bob Michell's group at a 
meeting at the Royal Society in London: that PtdIns(4,5)P2, not PtdIns, might be the 
primary target for receptor-mediated stimulated inositol lipid turnover [7]. The 
experiment failed completely (not surprisingly, as platelets take up inositol very poorly 
and you need financial resources beyond ours to succeed!) and as that was the only cell 
system I had up and running I had more or less given up on the whole question. Bernie 
Agranoff and his colleagues did succeed in doing this in platelets around the same time, 
but used the more heroic approach of [32P] labelling [8]. 
 That March, Rex and I received a phone call from Mike Berridge down in 
Cambridge saying that he and Pete Downes had been collaborating doing more or less the 
same thing in other tissues (which took up [3H]-inositol much better than platelets did), 
but were in a bit of confusion in trying to identify what was what. Mike and I had 
recently collaborated on a joint project looking at products that resulted from PtdIns 
hydrolysis by phospholipases secreted by blowfly salivary glands [9] so we were each 
aware of each other's respective expertise in Ca2+ (Mike) and inositides (me). I had never 
met Pete, though I knew his name from his publications. He was that day in March 
wearing a jumper identical to mine and as we are superficially similar in appearance a 
number of people in the Department took us for brothers; we couldn't decide which of us 
was most insulted. At that meeting it was decided that I would analyse by our various 
analytical techniques the ammonium formate eluates from Mike and Pete's Dowex 
columns, and also their unprocessed cell extracts. Together we hoped that we could 
produce the first report of different InsPs produced by various cells, which would be as 
definitive as possible with well-characterised compounds - a laudable aim that almost 
succeeded. 
 It took quite a few months and many scintillation vials (cutting paper 
ionophoretograms into strips has that inevitable consequence) to do it all. There was a 
hold-up for about two months because the InsP2 that parotid glands were producing 
would not co-chromatograph in a paper chromatography system with the InsP2 standard 
that we had. Neville Clarke, Rex's technician, had produced this InsP2 standard by acid 
hydrolysis of purified PtdIns4P from brain, so this result was not entirely surprising when 
we thought about it: in an acid hydrolysate there will be little if any of the 1,4 isomer of 
InsP2 present due to acid-catalysed phosphate migration [10]. It was not until eventually I 
managed to make a small quantity of [32P]Ins(1,4)P2, prepared enzymatically from red 
cells, that we could convince ourselves that parotid glands were producing the right stuff; 
that turned out to be a critically useful lesson in isomers (see below). 
 The delay was not entirely wasted, as during this time Pete had talked with a 
neighbour, Bill Schwartz in the MRC Laboratory of Molecular Biology, who had an 
FPLC system up and running (one of the first in the U.K., as this technology had only 
been launched the year before). Pete persuaded Bill to put a parotid gland extract onto a 
MonoQ column and by using acetate instead of formate they managed to achieve the 
lovely sharp peaks that only a high-performance system can give. Pete and I agreed that it 
would make a nice pretty picture to put in the Biochem J paper we were planning [11] if 
we added some of the [32P]Ins(1,4)P2 and [32P]Ins(1,4,5)P3 I had made from red cells to 
the tritium-labelled parotid extract, and we could then show a beautiful co-
chromatography of the two isotopes. Unfortunately (or fortunately with hindsight) the 
experiment backfired, as in the InsP3 region of the column eluate we could not persuade 
the tritium (from the parotid InsP3) and the [32P] (from the red cells) to co-elute exactly, 
and in the end we had to leave out the planned Figure (Fig 1) and put in a Table instead! 
That was something we would have to look at further.  
 Shortly afterwards I ran some of the parotid InsP3 on a paper chromatographic 
system with [32P]InsP3 from red cells and put it down to autoradiograph for a week or 
two. The first thing that Dave Lander did when he was transferred to my lab in early 1983 
as an additional technician to Andy Letcher (both were stalwart participants in this entire 
story) was to develop the film and cut up the paper. As on the Mono Q column, the [32P] 
and [3H] were not co-chromatographing and this diminished any thoughts we had had of 
isotopic artefacts (e.g. tritium in the inositol ring altering the chromatographic behaviour 
of the InsP3) - something odd was going on. 
 Meanwhile, the manuscript describing the characterisation of the inositol 
phosphates in the various tissues [11] was prepared and submitted, Pete left Cambridge to 
take up a post-doc position at ICI in Cheshire, and Mike set about his elegant time-course 
experiments [12] using the techniques we had now characterised and verified. I, 
reluctantly, had to spend four months or so repeating some experiments on 'PtdIns 
phosphodiesterase' (which we now know is actually PI-PLC [13]) to sort out a confusion 
that had emerged from earlier work in the lab [14]. I should also add that the [32P]-
labelled InsP2 and InsP3 we made from red cells were merely by-products of the 
radioactive PtdIns(4,5)P2 that we were routinely making as a part of our studies in which 
we showed that ‘PtdIns(4,5)P2 phosphodiesterase' was probably the same enzyme as 
'PtdIns phosphodiesterase', but under physiological conditions and with a membrane 
substrate it had a high specificity for PtdIns(4,5)P2 [15]. These experiments were also 
going on throughout '82 and '83 - they were busy years! 
 Towards the end of 1982, Mike, inspired by his kinetic experiments [12], which 
suggested that Ins(1,4,5)P3 is an early, possibly primary, product of inositide turnover, 
thought about testing his hypothesis that it might be the second messenger responsible for 
Ca2+ mobilisation. He tried two approaches. He sent some InsP3 to Bob McBurney in 
Newcastle to inject into a neurone or two, which Bob duly did; not a lot happened 
[actually, injecting Ins(1,4,5)P3 into neurones often has little effect]. Also, in December 
1982 Mike went to a meeting in Amsterdam where he heard Irene Schülz describe the 
permeabilised pancreatic cell preparation that she and Hans-Peter Streb had set up in 
Frankfurt [16], and he realised that this was an excellent system in which to test InsP3’s 
second messenger role.  
 
 
1983 
 The permeabilised pancreatic acinar cell preparation, however, was also a blank, 
as Mike ruefully explained to me when I visited him in Cambridge one day in February 
'83. When I asked where the InsP3 came from he explained that it was from Neville 
Clarke. I told Mike that this would be an old standard prepared by acid hydrolysis of 
PtdIns(4,5)P2 and reminded him of my previous problem with an InsP2 standard from the 
same source. I pointed out that it was entirely possible that because of acid-catalysed 
phosphate migration there may be virtually no 1,4,5 isomer in Neville’s InsP3 and that if 
this was to be a second messenger, some kind of isomeric specificity seemed likely; it 
would be reasonable to try again using pure Ins(1,4,5)P3. At this he brightened and asked 
if I could make some of the genuine article. This I did, from human red cells using Pete 
Downes' method [17]. We had previously only used this method to make our radioactive 
Ins(1,4,5)P3, but I was pleased to find that we derived a reasonable mass (about 1-2 
µmoles) of Ins(1,4,5)P3 from a pint of blood, which looked pure on ionophoretograms, 
and we sent the first batch to Irene towards the end of February. 
 Mike has since recalled [18] that we received an excited phone call from Irene 
almost immediately, but in fact there was a long delay. Irene did phone to say that the 
sample had arrived, but it had been lost because the tube looked empty; Mike told her it 
was invisible and probably very potent, so just add water to the tube and proceed! (Joel 
Brown described to me a similar reaction when he was first given an "invisible" sample 
of Ins(1,4,5)P3 to test on Limulus  photoreceptors - it made the effects of the "solution" all 
the more spectacular.) I recall chatting one day in early April with Mike and Tim Rink, in 
Tim's lab in Cambridge, and glumly agreeing that no news from Irene was bad news and 
that it looked like another good idea had gone west. Then, later that month, Mike did 
indeed get a highly excited phone call - Irene was already drafting a manuscript as a 
result of a clear and potent effect of the InsP3, which mobilised Ca2+ in their system. 
 This produced a bit of a panic in Mike and me, as the prospect of artefacts of one 
sort or another loomed large. So during the first few weeks of May I prepared ten 
samples to send to Hans-Peter and Irene, which were controls of one sort or another (e.g. 
a blank InsP3 preparation prepared by omitting the Ca2+ from the incubation of the red 
cell ghosts that liberates the InsP3; phosphatase-treated InsP3; various other inositol 
phosphate samples that I had made during the preceding eight years in Rex’s lab; etc). I 
numbered these and Mike sent them "blind" to Frankfurt for testing. One pair of samples 
I decided to re-number (because I had accidentally inverted my logical numbering 
sequence for that particular pair) after I had photocopied the "key" for Mike, so only I 
knew they were interchanged. This was not a deliberate trick - I did it without thinking - 
but when later they were the only two which gave the "opposite" result to what was 
expected (to the disappointment of Irene, Hans-Peter and Mike) it gave us all a great 
boost in confidence when I revealed the change! 
 Mike was burning with impatience to get the manuscript off as he feared that if it 
was not published in 1983 it would get lost in a rush of 1984 publications (how right he 
was!) and when we submitted a manuscript to Nature in June we were still not entirely 
convinced of the inactivity of Ins(1,4)P2 - it is very difficult to prepare really clean 
Ins(1,4)P2 from red cells using the techniques I had. But by the time the manuscript came 
back with favourable referees comments (although worries about the specificity were 
expressed), I had, after a struggle, made an Ins(1,4)P2 prep that I was really happy with. It 
was unambiguously Ins(1,4)P2 and was >98% pure, and this preparation was only 1% as 
potent as Ins(1,4,5)P3 (so even that small effect was probably due to contamination with 
the latter). I also had made an InsP3 preparation that had been acid-treated (to randomise 
the phosphate moieties - see above), which I repurified and re-assayed for phosphorus, 
and Hans-Peter found that this was clearly much less potent than Ins(1,4,5)P3, implying 
that at least some isomeric specificity was operating. We were at last happy with the 
revised version, and as it finally appeared [19] [and reading it afresh now] it represents a 
very convincing case that Ins(1,4,5)P3 was indeed a very promising candidate to be the 
mediator of intracellular Ca2+ mobilisation. 
 Meanwhile, work on the InsP3 from parotid glands was still progressing. I mixed 
this [3H]InsP3 with the [32P]InsP3 from red cells and presented the mixture to the red cell 
'ghosts', which contain an InsP3 phosphatase that Pete Downes had discovered earlier as 
part of his Ph.D. [17]. Even when all the InsP3 from the red cells had been hydrolysed, a 
majority of the tritiated InsP3 was untouched, and this was the final straw that convinced 
me that we really did have a new compound to deal with. I already knew that it was an 
InsP3 because if I dephosphorylated it with alkaline phosphatase it yielded tritiated 
inositol rather than glucose, gluconurate etc. In June 1983 I attended a meeting in 
Harrison Hot Springs in Canada. This was memorable not least for an amazing bird-
watching trip in a speed boat with Pete and Bob Michell, and also (while I was away) a 
child visiting our home walked right through a glass door (unscathed, to my wife Sandi's 
enormous relief!). At the meeting Bill Sherman, Pete and I discussed what the mystery 
InsP3 might be. We agreed that the likeliest bet was Ins(2,4,5)P3, formed by acid-
quenching of cyclic Ins(1:2,4,5)P3, which we predicted might be present as a parallel 
with the cyclic Ins(1,2)P known to be formed during hydrolysis of PtdIns by PI-PLC 
[20]. [Much later, some cyclic InsP3 was found by Majerus' group in stimulated tissues 
[21].]  
  During this time I re-read, in much more detail than before, Clinton Ballou's 
classic papers [22, 23], which had established the structure of Ins(1,4,5)P3 (using heroic 
amounts of material extracted from 100+ cow brains!). There were three reasons for 
reading these papers again. Firstly, if we followed Ballou's methods we would get much 
more material than we obtained from red cells, and so we would reduce the continuous 
stream of preparations using expired blood obtained from the very helpful Roger Pepper 
at the Cambridge Blood Transfusion Centre. We could also prepare Ins(2,4,5)P3, a by-
product in the preparation [22, 23], at the same time, which would enable us to see if the 
mystery InsP3 was indeed that isomer. 
 Secondly, with the concept of isomeric specificity firmly in my mind (see above), 
it seemed to me rather ironic that no sooner had we used what we believed to be a pure, 
defined isomer of InsP3 to demonstrate Ca2+ mobilisation, than we realised that we might 
not have any idea what that isomer actually was! We now knew there were certainly two 
InsP3’s - one from red cells, which mobilised Ca2+ (see above), and the other, the major 
isomer produced in stimulated parotid slices. This produced the nightmare thought that 
the Ins(1,4,5)P3 that Ballou and colleagues had studied (or, more strictly, the 
PtdIns(4,5)P2 from which it was derived) may be a speciality of myelin (and hence 
enriched in cow brains), whereas the compound from red cells, the Ca2+ mobiliser and 
potential second messenger, might be an entirely different isomer. Clearly, it was 
imperative to repeat Ballou's extraction and separation methods exactly so that we could 
obtain the same compound that he did, which we could be sure was Ins(1,4,5)P3, and test 
it in various Ca2+-mobilising systems. 
  The third reason was that I saw no particular reason why the structural 
determination methodology that Ballou and his colleagues had pioneered (based in turn 
on Fischer's original strategies) should not be applied to trace quantities of radiolabelled 
inositol phosphates. I reckoned that we could use careful co-chromatography with 
markers in a selection of independent separation methods to identify the degradation 
products obtained from inositol phosphates by periodate oxidation, borohydride 
reduction, and dephosphorylation. Thus we could in principle determine the structure of 
the mystery InsP3 even if we only had a few thousand d.p.m. of radioactivity to work 
with. The three of us (Andy, Dave and I) began to do this (amidst all the other things we 
were doing, see above!) on the mystery parotid InsP3.  
 Some aspects were easier said than done. We frequently lost samples when trying 
to desalt them because we had so little mass to work with. Also, it was extraordinarily 
difficult to detect non-cyclic alditols on paper after chromatography in a boric acid-
containing solvent (much the most effective method for separations) if you use silver 
detection; Clinton Ballou had not had that problem, as he used benzidine-containing 
sprays for detection, and modern safety standards forbade us even having benzidine in the 
lab, let alone spraying papers with an aerosol of it. The fact that Ballou had done it for 
years and was still alive and well and living in California was dismissed by the Safety 
Officer (quite rightly) as "anecdotal".  
 Ionophoresis in NaOH, a powerful method for separating alditols invented by  
Frahn and Mills [24], which we adapted and found most useful, also gave us some 
entertainment with the large ionophoresis apparatus that we used. This was cooled with 
gallons of white spirit, and so was housed in a separate room equipped with a CO2 
'sprinkler' system - one whiff of smoke and the doors locked automatically, some massive 
lead weights dropped to hit a lever and the room was flooded with CO2 (so you had to get 
out fast). The NaOH dissolved everything in the tank over a period of time and until we 
introduced an all-glass apparatus we sometimes had leaks and loose electrodes to contend 
with, and there ensued several entertaining episodes of sparking electrodes. (The theory, 
calmly explained to me by Rex, is that it does not matter as long as there is no oxygen 
under the white spirit to ignite it, but theory is not always entirely re-assuring with an 
electrode cracking away merrily under a potential fireball!) 
 Before the November publication of Streb et al [19], the four authors of that paper 
met (for the first time for Hans-Peter and I) at a September meeting in Zeist, Holland, 
which was organized by John Williamson. The excited atmosphere at that meeting when 
Mike presented for the first time in public the data from the pancreatic acinar cells was 
extraordinary, and I can still recall it to send a thrill down my spine. The story had 
already by then received a strong boost by the elegant confirmation during the summer by 
Gillian Burgess and her colleagues in Jim Putney's lab. Mike had chatted with Jim earlier 
in the year, and as a result I had sent him some InsP3. Gillian used a different technique 
(45Ca2+ and EGTA-Ca2+ buffers), a different tissue (liver) and animal (guinea pig), yet 
InsP3 did the same thing with a near identical potency. Another of my most vivid 
memories of the time is Mike phoning me at home (actually he had to trace me to another 
house where I was baby-sitting) and he was almost leaping down the phone with 
excitement at Jim's news.  
 For Jim's lab I dreamt up another control whereby they received "blind" three 
samples eluted from adjacent strips of a preparative electrophoretogram of InsP3, only 
one of which contained the InsP3. Only that sample mobilised Ca2+ and did so with a 
potency (based on phosphorus mass) identical to the original raw material, and this was 
another major step towards convincing us all that there really was something in the whole 
idea. At the meeting in Zeist John Williamson's group also had a positive result from 
another sample of InsP3, which I had sent him, and so by the end of that meeting there 
was little serious doubt in anyone's minds that we did indeed have a new second 
messenger on our hands.  
 Moreover, shortly after the meeting I was able to make Ins(1,4)P2 and Ins(4,5)P2 
very pure by Clint Ballou's original methods (which included a three-to-four week 
preparative chromatography step). Hans-Peter and Irene showed the remarkable 
specificity of Ins(1,4,5)P3 in a beautiful experiment employing the new super-pure 
Ins(1,4)P2, Ins(4,5)P2, and (definitely genuine) Ins(1,4,5)P3, of which only the last of 
these had any effect at all and that was a huge release of Ca2+ (Fig 2). This particular 
experiment was never published as it was later superseded by more quantitative data [25], 
which I always thought was rather a pity, as for me especially it was a very important part 
of the strengthening feeling that this was no artefact. Rex and I had had some concerns 
about the likely ability of the two vicinal phosphates of Ins(1,4,5)P3 being able to bind 
Ca2+ strongly, but the low (about two orders of magnitude lower than Ins(1,4,5)P3) 
potency of Ins(4,5)P2 was definitely reassuring. [Our concerns were that the ability of the 
4 and 5 phosphates of Ins(1,4,5)P3 to bind Ca2+ could have led to artefactual changes in 
Ca2+ that were not a reflection of any physiological function. In fact because Gillian and 
her colleagues used buffered 45Ca2+ efflux as an assay this possibility was highly unlikely, 
but that did not stop me worrying. Moreover, as noted in the legend to Figure 2, the direct 
demonstration in this experiment that the effect of Ins(1,4,5)P3 was catalytic was very 
reassuring.]  
 We had been progressing steadily with these larger scale preparations of inositol 
phosphates from bovine brain by Clint Ballou's methods (which in turn used as a starting 
point the original 1949 inositol lipid preparation of Jordi Folch-Pi [26] - the old ones are 
the best!). By the time of the Zeist meeting we had our first Ins(1,4,5)P3/Ins(2,4,5)P3 
mixtures ready to test the chromatographic behaviour of the latter with respect to the 
parotid InsP3 on paper. That had taken longer than necessary because of very low yields 
of InsP3 from cow brains, these low yields being due to me quenching KOH solutions 
with HCl before loading onto Dowex columns in the formate form. It was a while before 
I realised that I should be using formic acid and that the Cl' was stripping the formate 
from the column so the InsP3 was not sticking; sometimes with the benefit of hindsight 
one's idiocy can be truly embarrassing.  
 We set a chromatography paper running with some of Pete's parotid InsP3 in it 
just before the Zeist meeting. Pete, by the way, was still supplying us with this at 
considerable trouble to himself - I don't think he was meant to be doing that at ICI, but he 
used to rush into the lab early to knock off a preparation of stimulated glands without 
them knowing and sent us the samples. That chromatogram told us unequivocally that the 
parotid InsP3 was not Ins(2,4,5)P3, and we already knew it was not Ins(1,4,5)P3, so now 
we knew for sure that we had an entirely new compound on our hands. Now we really 
had to get stuck into it, with an increasing sense of urgency heightened by Pete admitting 
publicly (he had no option under close questioning) at the Chilton Conference in Dallas 
in the first week of January 1984 that the InsP3 predominating in stimulated parotid 
glands was not Ins(1,4,5)P3.  
 
 
1984 
 The atmosphere at the Chilton Conference was almost as electric as that in Zeist, 
and during the first few months after that Andy, Dave and I spent a significant amount of 
our time making and checking the various inositol phosphates prepared from bovine 
brains, which during that year were to be added/microinjected to more cells and 
physiological systems than I could dream of. As the news spread around the world, 
especially following the publication of Streb et al [19], more and more people contacted 
Mike or myself (or we contacted them - just once or twice we ended up with some 
duplication and confusion because things were happening so fast). To these collaborators 
we sent some Ins(1,4,5)P3 (plus Ins(1,4)P2 and Ins(4,5)P2 as the principal controls) for 
testing on permeabilised cells [27],  membrane preparations [28, 29], and intact cells by 
microinjection [30-32]. Meanwhile, other (or indeed, often the same) groups were 
demonstrating the stimulated synthesis of InsP3 (isomer unspecified) by a wide range of 
agonists on many tissues. Although there were, as there should have been, some sceptical 
voices, it was amazing to see how this proliferation of positive reports swept along with it 
an almost instantaneous acceptance that Ins(1,4,5)P3 was here to stay and in May Mike 
and I began to write a review for Nature [33] in which we were able to summarise a large 
body of work that placed Ins(1,4,5)P3 firmly on its way to established second messenger 
status. 
 All this Ins(1,4,5)P3 and InsP2 production became pretty routine stuff to us in 
Babraham by now and my thoughts during the first months of 1984 were more often 
revolving around the unknown InsP3 from parotid glands. We had a lot of practical 
problems, as discussed above, and we had had more or less to re-invent the whole 
methodology. However, as is often the way of science, when it finally came good, it did 
so in a rush. Within one week in April we obtained beautiful data showing unequivocally 
that the mystery InsP3 was degrading by periodate oxidation, borohydride reduction and 
dephosphorylation to altritol, meaning that it was Ins(1,2,4)P3 or Ins(1,3,4)P3. We had 
already made several attempts, with varying degrees of failure, to hydrolyse the InsP3 to 
InsP species to get independent insight into the isomeric configuration. These 
experiments never gave us good quantitative data - we were assuming that strong alkaline 
hydrolysis would cause a non-specific release of phosphate moieties, but we now know 
that such hydrolysis of Ins(1,3,4)P3 initially gives you mostly Ins(1,3)P2 and Ins(1,4)P2, 
and hardly any Ins(3,4)P2. However, what our summed data on the InsPs we derived 
showed clearly was that we never derived any Ins2P  from the mystery InsP3, so 
Ins(1,2,4)P3 was ruled out as a possible structure, and that only left Ins(1,3,4)P3. 
 We submitted the manuscript to the Biochem J [34] and set about trying to find 
out where the Ins(1,3,4)P3 was coming from. I should add that during the time between 
submission and acceptance of the manuscript we had a horrendous thought that the [3H] 
myo-inositol might have another inositol contaminating it which could get into the lipids, 
and could generate an inositol trisphosphate which was not based on the myo-inositol 
ring; this was quickly eliminated thanks to the financial resources of ICI which enabled 
Pete to do a quick and very expensive [14C]inositol  experiment – [14C]-inositol is 
prepared by a method entirely different from that used to make [3H]-inositol. 
 As for where the Ins(1,3,4)P3 was coming from, within weeks of resolving the 
structure of Ins(1,3,4)P3 we also came within an inch of finding its origin by almost 
discovering both Ins(1,3,4,5)P4 and Ins(1,4,5)P3 3-kinase (see Fig 3). In early 1984 Hans-
Peter, Irene and I had done some experiments following the degradation of Ins(1,4,5)P3 
in permeabilised pancreatic acinar cells (to see if that degradation coincides with the re-
uptake of Ca2+). We found that Ins(1,4,5)P3 was converted by the cells in an ATP-
dependent manner into an "InsP3" which was resistant to the phosphatase in red cell 
'ghosts'. If we had had [3H]-Ins(1,4,5)P3 available then, the whole thing would have been 
cracked, but our [32P]-Ins(1,4,5)P3 that I sent to Germany was home-made, labelled 
mostly in the 5-phosphate, and I found that some of the inorganic phosphate released was 
re-incorporated into ATP. Thus when I examined the putative 5-phosphatase-resistant 
InsP3 it was mostly ATP, and the small amount of InsP3 which was left (which must have 
been Ins(1,3,4)P3 generated in the test tube) I interpreted as being the last remnants of the 
[32P]-Ins(1,4,5)P3 that we had originally added. This is yet another example of hindsight 
making things clearer, but I also remember that my thinking was not as sharp in 
April/May 1984 as it might have been owing to the unbelievably hectic rate at which 
things were happening scientifically (see above), plus a conference trip to Switzerland, 
Sandi having an operation, and right in the middle of it all (in the early hours of the 
morning that I left for Switzerland) my younger son being hospitalised with an 
unexpected attack of croup. Maybe without that lot the penny would have dropped! 
 We were very keen to find a way of separating the 1,3,4 and 1,4,5 isomers and 
tried all kinds of chromatographic strategies. A great stroke of luck came with the 
presence of Erik Änggård in the lab, on sabbatical leave from the Karolinska Institute, 
who was familiar with hplc, and it was he who shut himself away with the (only) hplc 
machine at Babraham on the far side of the Institute and eventually obtained good sharp 
resolutions of adenine nucleotides on a Partisil SAX column. We then tried our two 
InsP3s on his system, and achieved a beautiful baseline separation (improved shortly 
afterwards by me, accidentally making up the eluant to the wrong pH). It was unfortunate 
that despite strenuous efforts (and help from Hal Dixon) we could not avoid having 
inorganic phosphate in the eluant (thus making difficult any mass measurement by 
phosphate analysis). But it was a fine separation, which we published the following year 
[35]. [Although variations have been played on it since, it has remained one of the most 
widely-used procedures for separating inositol phosphate isomers and deacylated inositol 
lipids.] 
 Much of the data for ref [35] had been generated by the time our Nature review 
[33] appeared, so the tale of the two inositol trisphosphates remained closely entwined 
until the end of 1984. Indeed, I regard the elucidation of the isomeric configuration of 
Ins(1,3,4)P3 and the development of a way of separating it from Ins(1,4,5)P3 as being an 
important part of the Ins(1,4,5)P3 saga for two reasons additional to the fact that the 
stories were exactly contemporaneous. Firstly, even in those early days it was evident 
that the kinetics of ‘InsP3’ production and particularly its disappearance after stimulation 
(e.g. [36]) were often far from compatible with its proposed second messenger function 
(see also Robin Hesketh's News and Views on Streb et al [37]). Separate analysis of the 
1,4,5 isomer soon removed most of these kinetic concerns [35, 38]. Secondly, even 
though we had no idea where Ins(1,3,4)P3 was coming from, nor why it was there, the 
facts that we knew what it was, that we could separate it from Ins(1,4,5)P3, and that 
Ins(1,4,5)P3 was definitely the Ca2+ mobiliser, prevented a potential nightmare of 
confusion happening just as people were trying to take on board the idea of Ins(1,4,5)P3 
as a second messenger. So I always felt that the (comparative) clarification that resulted 
from our work on Ins(1,3,4)P3 helped a great deal towards the ensuing rapid acceptance 
of Ins(1,4,5)P3’s function. The astonishing pace with which things moved following 
Streb et al [19] is best illustrated by the fact that the 'definitive' review that Mike and I 
wrote on Ins(1,4,5)P3 as a second messenger for Nature [33] was published only one year 
and two weeks after those original observations [19]. 
 
 
Postscript (2015) 
 Of course, in the autumn of 1984 there was still a long way to go. Many of the 
experimental procedures with which we had grappled became routine techniques for us 
and others in the ensuing years (e.g. [39-45]). For me the hectic pace described above 
continued into 1985 when we discovered Ins(1,3,4,5)P4 and determined its isomeric 
configuration [4, 39]. At the same time, the hplc separation technique set up to analyse 
the two InsP3s and InsP4 began to reveal that higher inositol phosphates (e.g. InsP5 and 
InsP6) were ubiquitous in eukaryotes rather than a speciality of the plant kingdom or 
erythrocytes of a few vertebrate species [2, 46]. Then the discovery of Ins(1,4,5)P3 3-
kinase [40] not only completed the InsP3/InsP4 pathway (Fig 3) but enabled us to make 
Ins(1,3,4,5)P4 to test on experimental systems. The unravelling of the function of 
Ins(1,3,4,5)P4 has been a much longer and more tortuous path and we are only just 
beginning to see the light of some understanding now [47, 48]. Appreciation of the 
functions of some other higher inositol phosphates has proceeded at a much faster pace 
(e.g. [49-52]) and they continue to surprise us. Meanwhile, many aspects of the inositol 
lipid story have become well established, especially the 3-phosphorylated lipids, but there 
are still a huge number of unanswered questions to keep us all busy for decades to come 
(see ref [53] for a magisterial summary of the current state of play).  
 All this in itself serves to emphasise the remarkable rapidity with which 
Ins(1,4,5)P3 was accepted and then entered the textbooks. It is certainly unlikely that I 
will be involved again in such an exhilarating and frantic two and a half years as those 
described above. I can't say I'm entirely sorry that life is now a bit quieter! 
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Figure Legends 
 
Figure 1 
 
Inositol phosphates from carbachol-stimulated rat parotid slices. 
 
The first indications that inositol phosphate metabolism might be more complicated than 
we had thought. This Figure is reproduced from ref [34], though the experiment was 
performed in the summer/autumn of 1982 – see text. It shows the separation of [3H]-
inositol phosphates (open circles) extracted from carbachol-stimulated rat parotid slices 
on a Pharmacia fplc column. The triangles (left) are an internal InsP standard (mostly 
Ins2P), and the black circles are a mixture of [32P]-Ins(1,4)P2 and [32P]-Ins(1,4,5)P3 
prepared from red cell membranes. The InsP3 peaks labelled with the two isotopes (right) 
do not co-chromatograph exactly. 
 
Figure 2 
 
Specificity and stoichiometry of Ins(1,4,5)P3-stimulated Ca2+ release (free Ca2+ measured 
by a Ca2+ electrode) from permeabilised pancreatic cells (rat).  
 
This is a photocopy of an unpublished experiment performed by Hans-Peter Streb and 
Irene Schulz in late November 1983. For the experimental protocol see ref [19], but in 
brief, a permeabilised cell preparation is added to the buffer (which includes ATP), and 
the free Ca2+ levels drop (and so pCa rises) as Ca2+ is pumped into the intracellular stores 
(left). The axis is adjusted and then subsequent additions of Ins(1,4)P2 or Ins(4,5)P2 (both 
at successively 1μM and 5 μM) have little effect, but 1 μM Ins(1,4,5)P3 causes a large 
release of Ca2+. An additional (and important) conclusion from this experiment is that, as 
judged by the calibrating 10 nmoles Ca2+ (right), around 30 nmoles of Ca2+ are released 
by 3 nmoles (1μM in 3 ml) of Ins(1,4,5)P3 so the effect of Ins(1,4,5)P3 on Ca2+ release is 
catalytic. 
 
Figure 3 
 
The formation of Ins(1,3,4)P3 and Ins(1,3,4,5)P4.  
 
This Figure is reproduced from ref [40], which postdates this account, but it illustrates its 
denouement. Note the speculation that Ins(1,4)P2 is the breakdown product of 
Ins(1,3,4)P3, which we later found to be incorrect [41]. 
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